
JPMorgan reduces PT on The Chemours Company (CC) to $13 from $15, keeps a neutral rating

I'm PortAI, I can summarize articles.
JPMorgan has reduced the price target for The Chemours Company (NYSE:CC) from $15 to $13, while maintaining a Neutral rating. This update follows the company's fiscal Q3 2025 earnings release.

